Establishment of a PXB mouse supply system in the United States
First written in FY2016. 9 of 18 entries say "Advanced", first in FY2018. Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1ReframedAnnual report
「Cost of sales decreased from the same period of the previous year because KMT Hepatech,Inc., formerly our overseas production facility subsidiary, ended its production activities.」
The company states that it has changed from the previous path of maintaining and expanding KMT Hepatech,Inc. as a North American production base to a situation in which the company has ended its production activities. - FY2025ReframedAnnual report
「Our group decided to dissolve KMT Hepatech, which had been positioned as our North American production base, from a profitability standpoint. However, to meet still-solid demand for PXB mice, we will work to increase production in stages by outsourcing animal husbandry, while considering a future production expansion plan with a focus on investment efficiency.」
The company has changed its policy from the previous path of expanding KMT Hepatech as a North American production base to dissolving the company and pursuing phased production increases through outsourced animal husbandry, with a focus on investment efficiency. - FY2023AdvancedAnnual report
「As we have established a clear path toward production at the company in the fiscal year ending March 2023, we aim to contribute to earnings through stable production in the fiscal year ending March 2024.」
The company states that a path toward establishing production at KMT Hepatech,Inc. has become clear and sets a time-bound target of contributing to earnings through stable production in the fiscal year ending March 2024. - FY2023-Q3RestatedAnnual report
「As part of this structure, we are making capital investments at KMT Hepatech,Inc., our overseas production base, to increase PXB mouse supply capacity. Going forward, we aim to stabilize PXB mouse production at the company while working to reduce costs through greater efficiency.」
The company has reaffirmed its policy of making capital investments at KMT Hepatech,Inc., increasing supply capacity, stabilizing production and reducing costs through greater efficiency. - FY2023-Q2RestatedAnnual report
「As part of this structure, we are making capital investments at KMT Hepatech,Inc., our overseas production base, to increase PXB mouse supply capacity. Going forward, we aim to stabilize PXB mouse production at the company while working to reduce costs through greater efficiency.」
The company has reaffirmed its policy of increasing supply capacity through capital investment at KMT Hepatech,Inc. and seeking to stabilize production and reduce costs through greater efficiency. - FY2023-Q1RestatedAnnual report
「As part of this structure, we are making capital investments at KMT Hepatech,Inc., our overseas production base, to increase PXB mouse supply capacity. Going forward, we aim to stabilize PXB mouse production at the company while working to reduce costs through greater efficiency.」
The company has reaffirmed its policy of increasing supply capacity through capital investment at KMT Hepatech,Inc. and seeking to stabilize production and reduce costs through greater efficiency. - FY2022WorsenedAnnual report
「Although we made the capital investment in August 2020 to meet growing demand for PXB mice and PXB-cells, we have not yet achieved sufficient production results to monetize the business. We recognize that establishing a production structure at the company is an urgent issue in order to meet current strong demand. We aim to establish production early in the fiscal year ending March 2023 and contribute to earnings.」
Even after the capital investment, KMT Hepatech,Inc. had not achieved sufficient production results or monetization, and the company has again set establishing a production structure as an early target for the fiscal year ending March 2023. - FY2022-Q1AdvancedAnnual report
「As part of this structure, we will advance capital investment and personnel development at KMT Hepatech,Inc., our overseas production base, increase PXB mouse supply capacity and work to reduce costs through more efficient production.」
The company explicitly states that it is advancing capital investment and personnel development at KMT Hepatech,Inc. to increase supply capacity and reduce costs through more efficient production. - FY2021AchievedAnnual report
「In August 2020, we completed the capital investment undertaken to meet growing demand for PXB mice and PXB-cells, establishing a full-scale production structure.」
The company states that capital investment at KMT Hepatech,Inc. was completed in August 2020, establishing a full-scale North American production structure. - FY2021-Q3AdvancedAnnual report
「This was mainly attributable to the expansion of PXB mouse production facilities at an overseas subsidiary, which increased buildings and structures by ¥85.636 million and tools, fixtures and equipment by ¥70.324 million.」
The expansion of PXB mouse production facilities at the overseas production base progressed, reflected in increases of ¥85.636 million in buildings and structures and ¥70.324 million in tools, fixtures and equipment. - FY2021-Q2AdvancedAnnual report
「This was mainly attributable to the expansion of PXB mouse production facilities at an overseas subsidiary, which increased construction in progress by ¥125.054 million.」
The company disclosed that the expansion of PXB mouse production facilities at its overseas production base increased construction in progress by ¥125.054 million. Capital investment to increase supply capacity is making concrete progress. - FY2021-Q1AdvancedAnnual report
「At KMT Hepatech,Inc., our overseas production base, we will advance capital investment and personnel development, increase PXB mouse supply capacity and work to reduce costs through more efficient production.」
The company is advancing capital investment and personnel development at KMT Hepatech,Inc. to increase PXB mouse supply capacity and improve production efficiency. Construction in progress increased by ¥63.230 million due to the expansion of facilities. - FY2020AdvancedAnnual report
「However, although PXB mouse production has begun at our subsidiary KMT Hepatech,Inc., it has not yet contributed to earnings, partly because construction of the new facility was delayed, and the operating loss continued.」
The company states that PXB mouse production began at KMT Hepatech,Inc., marking further progress toward establishing a North American production base, but that delayed construction of the new facility prevented a contribution to earnings. - FY2019AdvancedAnnual report
「Meanwhile, from an earnings perspective, substantial upfront costs were incurred at our subsidiary KMT Hepatech,Inc., where capital investment is being made to establish an overseas production base for PXB mice.」
The company states that capital investment was carried out at KMT Hepatech,Inc. to establish an overseas production base, and that the business has reached the stage at which upfront costs are being incurred. - FY2019-Q3AdvancedAnnual report
「Meanwhile, our subsidiary KMT Hepatech,Inc. is preparing to serve as an overseas production base for PXB mice, and upfront costs related to technical guidance and production studies have been incurred.」
The company states that KMT Hepatech,Inc. is at the stage of advancing technical guidance and production studies to establish it as an overseas production base for PXB mice, and that upfront costs have been incurred. - FY2018AdvancedAnnual report
「In March 2015, we began outsourcing PXB mouse production to Charles River Laboratories,Inc. in the United States. In addition, in November 2017, we acquired the shares of KMT Hepatech,Inc. of Canada, which, like our company, provides contract testing services using human hepatocyte chimeric mice, making it a wholly owned subsidiary. Going forward, we will make capital investments and transfer technology to enable PXB mouse production at KMT Hepatech,Inc., develop the PXB mouse supply structure to meet pharmaceutical companies' requirements, and train and assign personnel in North America who are familiar with PXB mouse production and can address various problems, with a view to increasing production in North America.」
In addition to outsourcing U.S. production to Charles River, the company made KMT Hepatech,Inc. a wholly owned subsidiary and moved into the stage of advancing capital investment, technology transfer and personnel deployment for production at KMT. - FY2017RestatedAnnual report
「We transferred PXB mouse production know-how to Charles River Laboratories,Inc. in the United States, secured a production base there and began full-scale supply in March 2015. Going forward, we will develop the PXB mouse supply structure to meet pharmaceutical companies' requirements and prepare to assign personnel to North America who are familiar with PXB mouse production and can address various problems, with a view to increasing production in North America.」
The company reiterates its U.S. production base and full-scale supply launch and indicates preparations to strengthen the supply structure and assign personnel in preparation for increased production in North America. - FY2016AchievedAnnual report
「Because establishing a supply structure in the United States is essential for our group's future business expansion, we transferred PXB mouse production know-how to Charles River Laboratories,Inc. in the United States, secured a production base there, and began full-scale supply in March 2015.」
The company states that it secured a U.S. production base and began full-scale supply in March 2015.